Merck Pipeline

1 Merck PipelineQ4 2021 Reflecting Pipeline toOct 27, 2021 Lead-in languageThe chart below reflects the company s research Pipeline as of Oct 27, 2021. Candidates shown in Phase 3 include specific products and the date such candidate entered intoPhase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a giventherapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer and certain other indications)

2 And additional claims, line extensions or formulations for in-line products are not 2 Phase 2 Phase 2 Phase 2 Phase 2 Phase 2 Phase 2 Phase 2 Phase 2 Phase 2 CancerHematological malignanciesMK-1026 RespiratorysyncytialvirusMK-1654 CancerBreastNSCLCMK-2140 CancerHematologicalmalignanciesNSCLC favezelimabMK-42802 PulmonaryArterial HypertensionMK-5475 CancerBreastNSCLCSCLCHNSCCE sophagealGastricProstateMelanomaladiratu zumabvedotinMK-64401,3 CancerCRCG astricAdvancedSolidTumorsEndometrialNSCL CB ladderBiliaryCervicalTUKYSA MK-71191 CancerBiliaryCervicalEsophagealBreastEnd ometrialProstateHeme MalignanciesVibostolimab+pembrolizumabMK -7684 AHIV-1 InfectionIslatravir+MK-8507MK-8591 BChikungunya virusVaccineV184 CancerNSCLC quavonlimabMK-13082 Treatment Resistant DepressionMK-1942 CancerAdvancedsolid tumorsKEYTRUDA MK-3475 CancerRCCSCLC favezelimab+pembrolizumabMK-4280 ACancerNSCLCSCLCMK-58902 CancerRare cancersCRCP ancreaticBiliaryCertain VHL tumors (EU)

3 WELIREG MK-64823 CancerAdvanced solidtumorsLYNPARZA MK-79021,2 Pneumococcal VaccineAdultV116 CancerBreastCutaneous SquamousCell CarcinomaHNSCCM elanomaSolidTumorsV937 CancerCRCH epatocellularSCLCM elanomaAdvanced Solid Tumorsquavonlimab+pembrolizumabMK-1308 ACardiovascularMK-2060 NASHMK-3655 CancerNSCLCSCLCMK-4830 NASHMK-6024 Overgrowth syndromeMK-7075 CancerMelanomaMK-76842 SchizophreniaMK-8189 HIV-1 InfectionIslatravir+ developed in a developed in combination with developed as monotherapy and/or in combination with KeytrudaMerck Pipeline as of Oct 27, 2021 Moved forward since last Pipeline 3 Phase 3 Phase 3 CancerRCCquavonlimab+pembrolizumabMK-130 8 ACancerBreastTUKYSA MK-71191 HIV-1 preventionislatravirMK-8591 CancerBiliary tractCervical (EU)Cutaneous Squamous Cell Carcinoma (EU)Gastric (EU)Hepatocellular (EU)MesotheliomaOvarianProstateSCLCKEYTR UDA MK-3475 CancerNSCLCC olorectalSCLCLYNPARZA MK-73391,3 HIV-1 infection doravirine+islatravirMK-8591A CancerNSCLCMK-7684 ACancerNSCLCP embrolizumab subcutaneousMK-3475 CancerRCCWELIREG MK-64823 Cancer HNSCCM elanomaCRCE sophagealNSCLCG astricLENVIMA MK-79021,2 Merck Pipeline as of Oct 27, developed in a developed in combination with developed as monotherapy and/or in combination with KeytrudaMoved forward since last Pipeline EntitiesUnder ReviewNew Molecular EntitiesApprovals1 NewMolecular EntitiesApprovals1 NewMolecular EntitiesApprovals1 NewMolecular EntitiesApprovals1 CoughgefapixantMK-7264(US, JPN, EU)

4 Heart failureVERQUVO MK-12422(US, JPN, EU)Fungal infectionNOXAFIL MK-5592(JPN, CHN)HPV VaccineGirls and womenSILGARD 9V503(JPN)VHL-aRCCWELIREG MK-6482(US)PneumococcalVaccineAdultV-114 (EU, JPN)HIV-1 infectionPIFELTRO MK-1439(JPN, CHN)Pediatric neurofibromatosis type-1 KOSELUGO MK-56182(US, EU)Ebola vaccineERVEBO V920(US, EU)Anti-ViralCOVID-19molnupiravirMK-4482 (US, EU)HIV-1 infectionDELSTRIGO doravirine+ lamivudine+ tenofovir disoproxil fumarateMK-1439A(CHN)Bacterial infectionRECARBRIO relebactam+imipenem/cilastatinMK-7655A(E U, JPN)PneumococcalVaccineAdultVAXNEUVANCE V-114(US) Merck Pipeline as of Oct 27, obtained within the last 24 developed in a collaborationMoved forward since last Pipeline Pipeline as of Oct 27, 20216 Certain Supplemental FilingsUnder ReviewCertain Supplemental FilingsUnder ReviewCertain Supplemental FilingsUnder ReviewcSSTIand Sepsis for pediatric useCUBICIN MK-3009(JPN)AdjuvantRenal Cell Cancer(KN564)KEYTRUDA MK-3475(US, EU, JPN)Advanced unresectable renal cell carcinoma (KN581)LENVIMA MK-79021,2(EU, JPN)MSI-H or dMMRE ndometrial Cancer(KN158)KEYTRUDA MK-3475(US)Cervical Cancer(KN826)KEYTRUDA MK-3475(JPN)Invasive AspergillosisNOXAFIL MK-5592(EU)TMB-H(KN158)KEYTRUDA MK-3475(JPN)Advanced unresectable MetastaticEsophageal Cancer(KN590)KEYTRUDA MK-3475(JPN)

5 1stline metastatic hepatocellularcancer (KN524)LENVIMA MK-79021,2,3(US)High-risk early stageTNBC(KN522)KEYTRUDA MK-3475(EU, JPN)Advanced endometrialcancer(KN775)LENVIMA MK-79021,2(EU, JPN)Melanoma(KN716)KEYTRUDA MK-3475(US, EU) developed in a combination with July 2020, the FDA issued a CRL for Merck s and Eisai s applications. Merck and Eisai intend to submit additional data when available to the forward since last Pipeline SupplementalApprovals1 Certain SupplementalApprovals1 Certain SupplementalApprovals1 Certain SupplementalApprovals1 Certain SupplementalApprovals11stline metastatic non-small cell lung cancer (KN042)KEYTRUDA MK-34752(EU)Alternative dosing regimen (Q6W)KEYTRUDA MK-3475(US,CHN,JPN, EU)Recurrent LA or metastatic esophageal cancer(KN180/KN181)KEYTRUDA MK-3475(CHN, JPN)1st line metastatic squamous non-small cell lung cancer (KN407)KEYTRUDA MK-3475(CHN)1st line esophagealcancer (KN590)KEYTRUDA MK-3475(US, EU, CHN)1st line head and neck cancer (KN048)KEYTRUDA MK-3475(EU, JPN, CHN)Previouslytreated tumor mutational burden-high(KN158)KEYTRUDA MK-3475(US)

6 Refractory classical Hodgkin lymphoma (rrcHL)(KN204)KEYTRUDA MK-3475(US, EU)1st line advanced renal cell carcinoma (KN426)KEYTRUDA MK-3475(JPN)Recurrent LA or metastatic cutaneous squamous cell carcinoma(KN629)KEYTRUDA MK-3475(US)Non-muscleinvasive bladdercancer(NMIBC)(KN057)KEYTRUDA MK-3475(US)Unresectable or Metastatic MSI-H or dMMRC olorectal Cancer (KN177)KEYTRUDA MK-3475(US, EU, CHN, JPN)Metastatic TNBC(KN355)KEYTRUDA MK-3475(US, EU, JPN)High-risk early stageTNBC(KN522)KEYTRUDA MK-3475(US)Metastatic HER2+Gastric Cancer(KN811)KEYTRUDA MK-3475(US)Cervical Cancer(KN826)KEYTRUDA MK-3475(US) Merck Pipeline as of Oct 27, obtained within the last 24 recommended results be included in the medicine s product information but did not recommend an extension of indicationMoved forward since last Pipeline Pipeline as of Oct 27, 20218 Certain SupplementalApprovals1 Certain SupplementalApprovals1 Certain SupplementalApprovals1 Certain SupplementalApprovals1 Certain SupplementalApprovals1 Certain SupplementalApprovals1 Invasive AspergillosisNOXAFIL MK-5592(US, JPN)1st linemaintenancenewlydiagnosedadvanced ovarian cancer(PAOLA)LYNPARZA MK-73392(US, EU,JPN)HABP/VABPRECARBRIO relebactam+imipenem/cilastatinMK-7655A(U S, EU)Thymic Carcinoma(NCCH1508/REMORA)LENVIMA MK-79021, 2(JPN)HPV VaccineGirls & Women(9-45yrs.)

7 GARDASIL V501(CHN)Advanced unresectable renal cell carcinoma (KN581)LENVIMA MK-79021,2(US)1stline advancedovarian cancer(SOLO-1)LYNPARZA MK-73392(CHN)Metastaticprostatecancer(PR Ofound)LYNPARZA MK-73392(US,EU, JPN,CHN)Differentiated ThyroidcancerLENVIMA MK-79022(CHN)Neuromuscular blockade reversalPediatricBRIDION MK-8616 HPV VaccineHPV related anal diseaseinmenGARDASIL V501(JPN)1st line gBRCAmPancreatic Cancer(POLO)LYNPARZA MK-73392(US,EU, JPN)HABP/VABPZERBAXA ceftolozane+ tazobactamMK-7625A(JPN)Advancedendometri alcancer(not-MSI-H/dMMR)(KN775)LENVIMA MK-79021,2(US)DiabetesSTEGLATRO MK-88352(CHN)HPV VaccineCertain HPVrelatedH&NcancersGARDASIL 9V503(US) obtained within the last 24 developed in a combination with KEYTRUDAM oved forward since last Pipeline statementThis presentation ofMerck & Co.

8 , Inc., Kenilworth, , USA (the company ) includes forward-looking statements within the meaning of thesafe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs andexpectations of the company s management and are subject to significant risks and uncertainties. There can be no guarantees with respect topipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. Ifunderlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in theforward-looking and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interestrate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact ofpharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care costcontainment; technological advances, new products and patents attained by competitors; challenges inherent in new product development,including obtaining regulatory approval.

9 The company s ability to accurately predict future market conditions; manufacturing difficulties or delays;financial instability of international economies and sovereign risk; dependence on the effectiveness of the company s patents and otherprotections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future eventsor otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be foundin the company s 2020 Annual Report on Form 10-K and the company s other filings with the Securities and Exchange Commission (SEC) availableat the SEC s Internet site ( ).

10 9No duty to updateThe information contained in the presentation set forth below was current as of Oct 27, 2021. While this presentation remains on the company s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after Oct 27, chart reflects the Merck research Pipeline as of Oct 27, shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not